Sex, Drugs and Aegerion (AEGR)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Stocks fall as higher oil prices, Treasury yields weigh
- Oppenheimer sees AI software winners as focus shifts to ROI
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
BofA/Merrill Lynch Downgrades Aegerion Pharmaceuticals (AEGR) to Underperform
October 31, 2014 8:26 AM EDTBofA/Merrill Lynch downgraded Aegerion Pharmaceuticals (NASDAQ: AEGR) from Buy to Underperform with a price target of $28.00 (from $48.00).
For an analyst ratings summary and ratings history on Aegerion Pharmaceuticals click here. For more ratings news on Aegerion Pharmaceuticals click here.
Shares of Aegerion Pharmaceuticals closed at $34.21 yesterday.
... MoreNeedham & Company Downgrades Aegerion Pharmaceuticals (AEGR) to Hold
October 31, 2014 8:01 AM EDTNeedham & Company downgraded Aegerion Pharmaceuticals (NASDAQ: AEGR) from Buy to Hold.
Analyst Chad Messer commented, "Aegerion reported disappointing 3Q:14 Juxtapid sales, lowered 2014 guidance, and introduced a lackluster sales forecast for 2015. Much higher than expected patient drop out rates appear to be the biggest... More
Jefferies Downgrades Aegerion Pharmaceuticals (AEGR) to Hold
October 31, 2014 7:17 AM EDTJefferies downgraded Aegerion Pharmaceuticals (NASDAQ: AEGR) from Buy to Hold with a price target of $24.00 (from $61.00).
Analyst Eun K. Yang comments, "Despite the complexities of ultra-orphan drug launch & learning curve, 2x miss in sales/2x downward revisions in FY14 guidance (by ~5%/18%) leave little room... More
Deutsche Bank Downgrades Aegerion Pharmaceuticals (AEGR) to Hold
October 31, 2014 6:57 AM EDTDeutsche Bank downgraded Aegerion Pharmaceuticals (NASDAQ: AEGR) from Buy to Hold with a price target of $26.00 (from $58.00).
Analyst Robyn Karnauskas said, "The co missed Q3 Juxtapid revs by $5M ($44M vs. $49M consensus) and decreased guidance significantly to $150-160M... More
JPMorgan Downgrades Aegerion Pharmaceuticals (AEGR) to Neutral
October 31, 2014 6:41 AM EDTJPMorgan downgraded Aegerion Pharmaceuticals (NASDAQ: AEGR) from Overweight to Neutral with a price target of $23.00 (from $48.00).
For an analyst ratings summary and ratings history on Aegerion Pharmaceuticals click here. For more ratings news on Aegerion Pharmaceuticals click here.
Shares of Aegerion Pharmaceuticals closed at $34.21 yesterday.
... MoreAegerion Pharmaceuticals (AEGR) Misses Q3 EPS by 6c, Lowers JUXTAPID Guidance
October 30, 2014 4:36 PM EDTAegerion Pharmaceuticals (NASDAQ: AEGR) reported Q3 EPS of ($0.20), $0.06 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $43.7 million versus the consensus estimate of $48.6 million.
2014 and 2015 Financial Guidance
Aegerion stated the following financial guidance:
Aegerion now expects full-year JUXTAPID... More
